



ATTORNEY DOCKET NO. B45331-2	
Form PTO-1595	U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office
RECORDATION FORM COVER SHEET - PATENTS ONLY	
CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office Assignment Branch at (571) 273-0140 on <u>15 September 2006</u> by Marie Williams	
	
Commissioner of Patents: Please record the attached original documents or copy thereof.	
1. Name of conveying party(ies) Gary DUBIN Bruce INNIS Moncef Mohammed SLAOU Martine Anne Cecile WETTENDORFF Additional names of conveying party(ies) attached? <input type="checkbox"/> yes <input checked="" type="checkbox"/> no	2. Name and address of receiving party(ies) GlaxoSmithKline Biologicals s.a. rue de l'Institut 89, B01330 Rixensart Belgium Additional name(s) and addresses attached? <input type="checkbox"/> yes <input checked="" type="checkbox"/> no
3. Description of the interest conveyed: <input checked="" type="checkbox"/> Assignment, please record and return <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other Execution dates of Assignment: August 22, 2006 September 7, 8, and 11, 2006.	
4. Application number(s) or patent number(s). Additional Sheets attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
A. Patent Application No.(s) 11/367,601	B. Patent No.(s)
5. Name and address of party to whom correspondence concerning documents should be mailed: William R. Majarian GlaxoSmithKline Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Fax: (610) 270-5090	6. Total number of applications and patents involved <u>1</u> . 7. Total Fee (37 C.F.R. 3.41) <u>\$40.00</u> 8. Please charge this fee to deposit account No. <u>19-2570</u> . The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this paper, or credit any overpayment, to our Deposit Account No. 19-2570.
DO NOT USE THIS SPACE	
9. Statement and Signature. <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i>	
<u>William R. Majarian</u> Name of Person Signing	 Signature
	<u>September 15, 2006</u> Date
Total number of pages including cover sheet, attachments and document: <u>2</u>	

N:\W\NAPPS\B-cases\B45331-2 - Record Assignment Cover Sheet.doc

Docket No.: B45331-2

ASSIGNMENT

WHEREAS we, Gary DUBIN of King of Prussia, Pennsylvania 19406, a citizen of United States of America; Bruce INNIS of King of Prussia, Pennsylvania 19406, a citizen of United States of America; and Moncef Mohammed SLAOUI of King of Prussia, Pennsylvania 19406, a citizen of Belgium; Martine Anne Cecile WETTENDORFF of Rixensart, Belgium, B-1330, a citizen of Belgium; have made an invention entitled:

"VACCINE"


for which on an even we executed an application for Letters Patent of the United States under 35 U.S.C. §111(a), executed an application for Letters Patents of the United States under 35 U.S.C. §371, or filed a Provisional application under 35 U.S.C. §111(b):

NOW, THEREFORE, in return for valuable consideration paid to us by GlaxoSmithKline Biologicals sa, a corporation organized under the laws of Belgium and having its principal place of business at rue de l'Institut 89, B01330 Rixensart Belgium, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, we do hereby assign unto the said GlaxoSmithKline Biologicals sa, its successors and assigns, the entire right, title and interest in and to the said invention, executed under 35 U.S.C. §111(a), 35 U.S.C. §371, or filed under 35 U.S.C. §111(b) application, and from which priority may be claimed from one or more 35 U.S.C. §111(b) applications, or any division, continuation and continuation-in-part of said application, and all Letters Patent of the United States and all foreign countries to be obtained therefor;

We further assign to the said GlaxoSmithKline Biologicals sa the right, optionally in its own name or in the names of its related companies, to apply for, obtain and maintain in all countries foreign to the United States, patent and/or Utility Model applications for said invention, including the full right to claim for any such application the benefits of any priority rights based on said executed United States application;


And we agree to execute further instruments (including provisional, divisional, continuation, continuation-in-part or reissue applications or other instruments) proper to effectuate the premises, this agreement to be binding upon our heirs, executors and administrators;

And we request the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue Letters Patent in accordance herewith.



 Gary DUBIN

Date: 7 Sept 06



 Bruce INNIS

Date: 8 Sep 2006



 Moncef Mohammed SLAOUI

Date: Sept 11, 2006



 Martine Anne Cecile WETTENDORFF

Date: 22 August 2006

PATENT

RECORDED: 09/15/2006

REEL: 018270 FRAME: 0684